Vanguard Group Inc. Lowers Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Vanguard Group Inc. lessened its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 923,890 shares of the company's stock after selling 32,165 shares during the period. Vanguard Group Inc. owned about 3.81% of OrthoPediatrics worth $21,416,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock valued at $94,000 after acquiring an additional 1,929 shares in the last quarter. State Street Corp lifted its holdings in OrthoPediatrics by 1.0% in the third quarter. State Street Corp now owns 417,898 shares of the company's stock worth $11,329,000 after buying an additional 4,236 shares during the period. Barclays PLC boosted its position in OrthoPediatrics by 319.3% during the 3rd quarter. Barclays PLC now owns 25,298 shares of the company's stock valued at $686,000 after acquiring an additional 19,264 shares in the last quarter. Geode Capital Management LLC raised its position in shares of OrthoPediatrics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 391,492 shares of the company's stock worth $10,615,000 after acquiring an additional 7,972 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its stake in shares of OrthoPediatrics by 1.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 251,588 shares of the company's stock valued at $5,832,000 after purchasing an additional 4,728 shares during the period. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Stock Up 2.0 %

OrthoPediatrics stock traded up $0.41 during trading hours on Friday, hitting $21.00. The stock had a trading volume of 103,576 shares, compared to its average volume of 198,451. The stock's 50-day moving average price is $23.87 and its 200-day moving average price is $24.58. OrthoPediatrics Corp. has a 12-month low of $20.26 and a 12-month high of $35.99. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $510.03 million, a P/E ratio of -17.07 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to analysts' expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period in the prior year, the firm posted ($0.23) EPS. Equities research analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, insider Gregory A. Odle sold 5,359 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the sale, the insider now directly owns 148,788 shares in the company, valued at $3,698,869.68. The trade was a 3.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares in the company, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,732 shares of company stock worth $589,978 over the last quarter. Company insiders own 31.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on KIDS shares. Stifel Nicolaus decreased their price objective on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Lake Street Capital started coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price objective on the stock. Truist Financial decreased their target price on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Needham & Company LLC restated a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.00.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.